SCHEMBL6880028

SCHEMBL6880028

Cc1nc2c(c(=O)n(CCCC(=O)O)c(=O)n2C)n1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNF P01375 6/20 0.56
▸ CYP1A2 P05177 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ ADORA2B P29275 2/20 0.45
▸ NFKB1 P19838 2/20 0.45
▸ ACHE P22303 2/20 0.45
▸ PDE4A P27815 2/20 0.45
▸ PMP22 Q01453 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ PDE4B Q07343 1/20 0.45
▸ PDE4C Q08493 1/20 0.45
▸ PDE4D Q08499 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.45
▸ HPGD P15428 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ ESR1 P03372 1/20 0.42
▸ MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11921632 0.92 TNF (0.52) TNFCYP1A2LMNAADORA2BNFKB1
SCHEMBL8060268 0.85 TNF (0.63) TNFCYP1A2LMNAADORA2BNFKB1
SCHEMBL18460236 0.85 TNF (0.52) TNFCYP1A2LMNAADORA2BNFKB1
SCHEMBL6878419 0.81 TNF (0.49) TNFCYP1A2LMNAADORA2BNFKB1
SCHEMBL15471352 0.80 TNF (0.48) TNFCYP1A2LMNAADORA2BNFKB1
SCHEMBL19975705 0.79 TNF (0.49) TNFCYP1A2LMNAADORA2BNFKB1
SCHEMBL19975702 0.78 TNF (0.46) TNFCYP1A2LMNAADORA2BNFKB1
SCHEMBL8126411 0.78 TNF (0.46) TNFCYP1A2LMNAADORA2BNFKB1
SCHEMBL19975701 0.78 TNF (0.46) TNFCYP1A2LMNAADORA2BNFKB1
1-[4-Carboxypropyl]-3,7-Dimethylxanthine SCHEMBL5420399 0.77 ADORA2B (0.74) TNFCYP1A2LMNAADORA2BNFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9918987-B2 Substituted xanthine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2018-03-20 — — US disclosed
US-20170027946-A1 SUBSTITUTED XANTHINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2017-02-02 — — US disclosed
US-9492457-B2 Substituted xanthine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2016-11-15 — — US disclosed
US-20150272956-A1 SUBSTITUTED XANTHINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2015-10-01 — — US disclosed
US-8987442-B2 Deuterium-substituted xanthine derivatives and methods of use CONCERT PHARMACEUTICALS, INC. (US) 2015-03-24 — — US disclosed
US-8263601-B2 Deuterium substituted xanthine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2012-09-11 — — US disclosed
US-20120202830-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. 2012-08-09 — — US disclosed
US-20110077255-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. 2011-03-31 — — US disclosed
US-20110053961-A1 SUBSTITUTED XANTHINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. 2011-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077255-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 TNF 583/4885CYP1A2 509/4885LMNA 2823/4885
US-20110053961-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 TNF 583/4885CYP1A2 509/4885LMNA 2823/4885
US-20120202830-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 TNF 583/4885CYP1A2 509/4885LMNA 2823/4885
US-20170027946-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 TNF 583/4885CYP1A2 509/4885LMNA 2823/4885
US-20150272956-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, HPRT1, CXCR3 TNF 583/4885CYP1A2 509/4885LMNA 2823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback